Serrated polyposis syndrome and the role of serrated polyps in colorectal cancer development

2012 ◽  
Vol 1 (1) ◽  
pp. 37-47
Author(s):  
Karam Singh Boparai ◽  
Yark Hazewinkel ◽  
Evelien Dekker
Author(s):  
J. Heijmans ◽  
N.V. Büller ◽  
V. Muncan ◽  
G.R. van den Brink

2017 ◽  
Vol 10 (5) ◽  
pp. 417-428 ◽  
Author(s):  
Sofia Oke ◽  
Alberto Martin

The intestinal microbiota consists of a dynamic organization of bacteria, viruses, archaea, and fungal species essential for maintaining gut homeostasis and protecting the host against pathogenic invasion. When dysregulated, the intestinal microbiota can contribute to colorectal cancer development. Though the microbiota is multifaceted in its ability to induce colorectal cancer, this review will focus on the capability of the microbiota to induce colorectal cancer through the modulation of immune function and the production of microbial-derived metabolites. We will also explore an experimental technique that is revolutionizing intestinal research. By elucidating the interactions of microbial species with epithelial tissue, and allowing for drug screening of patients with colorectal cancers, organoid development is a novel culturing technique that is innovating intestinal research. As a cancer that remains one of the leading causes of cancer-related deaths worldwide, it is imperative that scientific findings are translated into the creation of effective therapeutics to treat colorectal cancer.


2016 ◽  
Vol 310 (11) ◽  
pp. G1081-G1090 ◽  
Author(s):  
Yvette J. Merga ◽  
Adrian O'Hara ◽  
Michael D. Burkitt ◽  
Carrie A. Duckworth ◽  
Christopher S. Probert ◽  
...  

Chronic inflammation is a common factor in the development of many gastrointestinal malignancies. Examples include inflammatory bowel disease predisposing to colorectal cancer, Barrett's esophagus as a precursor of esophageal adenocarcinoma, and Helicobacter pylori-induced gastric cancer. The classical activation pathway of NF-κB signaling has been identified as regulating several sporadic and inflammation-associated gastrointestinal tract malignancies. Emerging evidence suggests that the alternative NF-κB signaling pathway also exerts a distinct influence on these processes. This review brings together current knowledge of the role of the alternative NF-κB signaling pathway in the gastrointestinal tract, with a particular emphasis on inflammation-associated cancer development.


2020 ◽  
Vol 57 (10) ◽  
pp. 677-682
Author(s):  
Coral Arnau-Collell ◽  
Yasmin Soares de Lima ◽  
Marcos Díaz-Gay ◽  
Jenifer Muñoz ◽  
Sabela Carballal ◽  
...  

BackgroundSerrated polyposis syndrome (SPS) is a clinical entity characterised by large and/ormultiple serrated polyps throughout the colon and increased risk for colorectal cancer (CRC). The basis for SPS genetic predisposition is largely unknown. Common, low-penetrance genetic variants have been consistently associated with CRC susceptibility, however, their role in SPS genetic predisposition has not been yet explored.ObjectiveThe aim of this study was to evaluate if common, low-penetrance genetic variants for CRC risk are also implicated in SPS genetic susceptibility.MethodsA case-control study was performed in 219 SPS patients and 548 asymptomatic controls analysing 65 CRC susceptibility variants. A risk prediction model for SPS predisposition was developed.ResultsStatistically significant associations with SPS were found for seven genetic variants (rs4779584-GREM1, rs16892766-EIF3H, rs3217810-CCND2, rs992157-PNKD1/TMBIM1, rs704017-ZMIZ1, rs11196172-TCF7L2, rs6061231-LAMA5). The GREM1 risk allele was remarkably over-represented in SPS cases compared with controls (OR=1.573, 1.21–2.04, p value=0.0006). A fourfold increase in SPS risk was observed when comparing subjects within the highest decile of variants (≥65) with those in the first decile (≤50).ConclusionsGenetic variants for CRC risk are also involved in SPS susceptibility, being the most relevant ones rs4779584-GREM1, rs16892766-EIF3H and rs3217810-CCND2.


2016 ◽  
Vol 150 (4) ◽  
pp. 895-902.e5 ◽  
Author(s):  
Rune Erichsen ◽  
John A. Baron ◽  
Stephen J. Hamilton-Dutoit ◽  
Dale C. Snover ◽  
Emina Emilia Torlakovic ◽  
...  

Meat Science ◽  
2014 ◽  
Vol 97 (4) ◽  
pp. 583-596 ◽  
Author(s):  
Marije Oostindjer ◽  
Jan Alexander ◽  
Gro V. Amdam ◽  
Grethe Andersen ◽  
Nathan S. Bryan ◽  
...  

2014 ◽  
Vol 146 (5) ◽  
pp. S-630
Author(s):  
Limas Kupcinskas ◽  
Alexander Link ◽  
Thomas Wex ◽  
Gediminas Kiudelis ◽  
Laimas Jonaitis ◽  
...  

Aging ◽  
2020 ◽  
Vol 12 (20) ◽  
pp. 20396-20412
Author(s):  
Weinan Xue ◽  
Fan Wang ◽  
Peng Han ◽  
Yanlong Liu ◽  
Bomiao Zhang ◽  
...  

2021 ◽  
Vol 22 (23) ◽  
pp. 12739
Author(s):  
Sofía Frigerio ◽  
Dalia A. Lartey ◽  
Geert R. D’Haens ◽  
Joep Grootjans

Patients with inflammatory bowel disease (IBD) have increased incidence of colorectal cancer (CRC). IBD-associated cancer follows a well-characterized sequence of intestinal epithelial changes, in which genetic mutations and molecular aberrations play a key role. IBD-associated cancer develops against a background of chronic inflammation and pro-inflammatory immune cells, and their products contribute to cancer development and progression. In recent years, the effect of the immunosuppressive microenvironment in cancer development and progression has gained more attention, mainly because of the unprecedented anti-tumor effects of immune checkpoint inhibitors in selected groups of patients. Even though IBD-associated cancer develops in the background of chronic inflammation which is associated with activation of endogenous anti-inflammatory or suppressive mechanisms, the potential role of an immunosuppressive microenvironment in these cancers is largely unknown. In this review, we outline the role of the immune system in promoting cancer development in chronic inflammatory diseases such as IBD, with a specific focus on the anti-inflammatory mechanisms and suppressive immune cells that may play a role in IBD-associated tumorigenesis.


Sign in / Sign up

Export Citation Format

Share Document